| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5583122 | APIL | Pharmaceutical compositions containing geminal diphosphonates |
Dec, 2013
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5622721 | APIL | Dosage forms of risedronate |
Apr, 2014
(10 years ago) | |
|
US5583122 (Pediatric) | APIL | Pharmaceutical compositions containing geminal diphosphonates |
Jun, 2014
(9 years ago) | |
| US8246989 | APIL | Dosage forms of bisphosphonates |
Jan, 2026
(1 year, 8 months from now) | |
| US7645460 | APIL | Dosage forms of risedronate |
Jan, 2028
(3 years from now) | |
| US7645459 | APIL | Dosage forms of bisphosphonates |
Jan, 2028
(3 years from now) | |
Atelvia is owned by Apil.
Atelvia contains Risedronate Sodium.
Atelvia has a total of 6 drug patents out of which 3 drug patents have expired.
Expired drug patents of Atelvia are:
- US5622721
- US5583122*PED
- US5583122
Atelvia was authorised for market use on 08 October, 2010.
Atelvia is available in tablet, delayed release;oral dosage forms.
Atelvia can be used as treatment of osteoporosis in postmenopausal women.
The generics of Atelvia are possible to be released after 09 January, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 08, 2013 |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 08 October, 2010
Treatment: Treatment of osteoporosis in postmenopausal women
Dosage: TABLET, DELAYED RELEASE;ORAL
ATELVIA family patents
